XTR003

DRUG2 trials

Sponsors

Sinotau Pharmaceutical Group

Conditions

Coronary Artery Disease (CAD)Ischemic Heart Disease (IHD)

Phase 1

A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers

CompletedNCT05136391

Sinotau Pharmaceutical GroupCoronary Artery Disease (CAD)

Start: 2021-03-29End: 2021-08-27Updated: 2021-12-15

Phase 2

XTR003 PET Radiotracer for the Detection of Viable Myocardium

CompletedNCT05885854

Sinotau Pharmaceutical GroupIschemic Heart Disease (IHD)

Start: 2021-12-15End: 2023-03-05Updated: 2023-06-02

Related Papers

XTR003, a fatty acid metabolism PET tracer: A phase I study to evaluate the safety, biodistribution, radiation dosimetry, and pharmacokinetics in healthy volunteers.

2025-02-071 citations